Rating Change
Wedbush reiterated its Outperform rating on Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on August 18, 2026.
reiterateNASDAQ:RNAC
Wedbush Reiterates Outperform Rating on Cartesian Therapeutics, Inc. (RNAC)
Wedbush reiterated its Outperform rating on Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on August 18, 2026.
At publication ·
What changed
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) · reiterate
- Firm
- Wedbush
- Rating
- Outperform to Outperform
- Price at event
- $9.20
- Market capitalization
- $222.6M
At a glance
Key takeaways
- Wedbush reiterated an Outperform rating on Cartesian Therapeutics (RNAC) on August 18, 2026, with the stock trading at $9.20 and a market capitalization of $222.6 million.
Market Context
Cartesian Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $9.20 with a market capitalization of $222.6M. The stock has declined 19.7% over the past 52 weeks.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Cartesian Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Cartesian Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | Wedbush | Outperform | N/A |
| Jun 10, 2026 | Wedbush | Outperform | N/A |
| Jun 09, 2026 | Needham | Buy | N/A |
| Jun 09, 2026 | BTIG | Buy | N/A |
| May 27, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View RNAC Stock Page
Frequently Asked Questions
What does the Outperform rating mean for RNAC?
A rating of Outperform from Wedbush reflects the analyst's outlook on Cartesian Therapeutics, Inc. (NASDAQ:RNAC). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RNAC forecast page.